Japanese medical electronic equipment maker Nihon Kohden has acquired a 71.4% stake in NeuroAdvanced, the parent company of Ad-Tech Medical Instrument (Ad-Tech) for JPY16bn ($103m).
Under the agreement, Nihon Kohden will acquire 227.76 shares of NeuroAdvanced. Ad-Tech will become consolidated and specified subsidiaries of the Tokyo-based company.
Ad-Tech is engaged in developing specialised electrodes used in epilepsy treatment and neurodiagnostics.
This acquisition strengthens Nihon Kohden’s position in electroencephalogram (EEG) systems with Ad-Tech’s intracranial electrodes.
It also enhances the Japanese firm’s ability to address complex neurological conditions, including drug-resistant epilepsy.
Nihon Kohden plans to combine its expertise in neurology diagnostics with Ad-Tech’s consumables to deliver more integrated care.
According to the medical electronic equipment maker, both companies have a presence in several US hospitals, making this acquisition a powerful synergy. The combination is anticipated to streamline adoption and improve care for clinicians and hospital systems nationwide.
Ad-Tech’s electrode devices are manufactured in the US and are used globally by healthcare providers to record, monitor, and stimulate deeper brain regions.
The products support long-term EEG monitoring, brain mapping, stereoelectroencephalography (sEEG), and brain stimulation. These devices help treat intractable epilepsy and other neurological disorders.
Founded in 1983, Ad-Tech has expanded globally, with products approved in over 60 countries, including markets in the US, Europe, and Japan.
Nihon Kohden America president Roy Sakai said: “This acquisition represents a pivotal step in advancing critical solutions for epilepsy care.
“By uniting our strengths, we’re enhancing our ability to provide end-to-end support for epilepsy from accurate diagnosis to advanced interventions.”
As part of Nihon Kohden’s Long-term Vision, BEACON 2030, the company aims to improve care throughout the patient and caregiver journey.
This collaboration supports critical care solutions, including intraoperative neuromonitoring (IONM), preserves function, and maximises patient data through advanced analytics and digital health solutions (DHS).
ARCHIMED, the former owner of Ad-Tech and an investment firm, will continue as a minority joint venture partner with the Japanese firm.
Nihon Kohden and ARCHIMED will collaborate to drive Ad-Tech’s continued global expansion.
